Clinical Trials Browser

Interventional × Triple Negative Breast Neoplasms × fludarabine × Clear all

Breast Neoplasms, Recurrence, Triple Negative Breast Neoplasms

NCT07297667 2026-04-13

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

Phase 1 Not yet recruiting

30 enrolled

BreastGenitourinarySarcoma

Carcinoma, Renal Cell, Sarcoma, Alveolar Soft Part, Triple Negative Breast Neoplasms

NCT07523529 2026-04-13

SELECT-2CAR

Phase 1/2 Recruiting

72 enrolled

BreastCNSGastrointestinalGenitourinaryGynecologic

Glioblastoma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT07486089 2026-03-20

DUAL-NK-BC

Phase 1/2 Recruiting

60 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05989828 2026-01-14

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

Phase 1 Suspended

20 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05035407 2025-12-02

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Phase 1 Terminated

36 enrolled 7 charts

Breast

Carcinoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03449108 2025-11-21

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Phase 2 Active not recruiting

30 enrolled

BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Phase 1/2 Active not recruiting

6 enrolled

BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT06532812 2024-11-12

BAH249

Phase 1/2 Recruiting

85 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04282044 2024-02-08

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

Phase 1 Recruiting

60 enrolled

BreastDermatologicGastrointestinalGynecologicSarcomaThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Osteosarcoma, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04025216 2024-01-24

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Phase 1 Terminated

16 enrolled

BreastGynecologicPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Multiple Myeloma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04551885 2023-09-21

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1 Terminated

12 enrolled

BreastDermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT05069935 2023-09-21

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1 Terminated

16 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04639245 2023-08-03

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Phase 1/2 Terminated

1 enrolled 6 charts

BreastGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Clinical Trials

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

SELECT-2CAR

DUAL-NK-BC

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

BAH249

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer